Target Name: LRRK1
NCBI ID: G79705
Other Name(s): FLJ27465 | leucine rich repeat kinase 1 | OTTHUMP00000230021 | KIAA1790 | LRRK1_HUMAN | FLJ23119 | Roco1 | Leucine-rich repeat kinase 1 | Leucine-rich repeat serine/threonine-protein kinase 1 | RIPK6 | Leucine rich repeat kinase 1 | OSMD

LRRK1 as A Potential Drug Target and Biomarker for Alzheimer's Disease

LRRK1 (FLJ27465) is a protein that is expressed in various tissues throughout the body, including the brain. It is a key regulator of the tau protein, which is a protein that is involved in the formation of neurofibrillary tangles that are thought to contribute to the development of Alzheimer's disease.

Recent studies have identified LRRK1 as a potential drug target for the treatment of Alzheimer's disease. By blocking the activity of LRRK1, researchers have found that they can reduce the formation of neurofibrillary tangles in animal models of Alzheimer's disease.

LRRK1 is also a potential biomarker for the early detection of Alzheimer's disease. By measuring the level of LRRK1 in brain tissue samples from people with Alzheimer's disease, researchers have found that the level of LRRK1 is significantly lower in the brain tissue of people with Alzheimer's disease compared to age-matched controls.

In addition to its potential as a drug target and biomarker, LRRK1 is also of interest because of its role in the regulation of other proteins. Studies have shown that LRRK1 can interact with a variety of other proteins, including the protein TAT2.

LRRK1 is also a target for several other drugs that are currently being developed for the treatment of Alzheimer's disease. For example, a drug called AC-1238 is currently being developed by a company called Akili Interactive as a potential treatment for Alzheimer's disease. This drug works by blocking the activity of LRRK1 and has been shown to increase the amount of neurofibrillary tangles that are removed from the brain in animal models of Alzheimer's disease.

LRRK1 is also a target for a drug called P502, which is being developed by a company called CuraTech. This drug is designed to block the activity of LRRK1 and has been shown to reduce the formation of neurofibrillary tangles in animal models of Alzheimer's disease.

While the potential use of LRRK1 as a drug target and biomarker for Alzheimer's disease is still in the early stages of research, it is clear that LRRK1 is an important protein that is involved in the development and progression of this disease. Further studies are needed to fully understand the role of LRRK1 in Alzheimer's disease and to develop safe and effective treatments.

Protein Name: Leucine Rich Repeat Kinase 1

Functions: Plays a role in the negative regulation of bone mass, acting through the maturation of osteoclasts

More Common Targets

LRRK2 | LRRN1 | LRRN2 | LRRN3 | LRRN4 | LRRN4CL | LRRTM1 | LRRTM2 | LRRTM3 | LRRTM4 | LRSAM1 | LRTM1 | LRTM2 | LRTOMT | LRWD1 | LSAMP | LSG1 | LSINCT5 | LSm Protein Complex | LSM1 | Lsm1-7 complex | LSM10 | LSM11 | LSM12 | LSM14A | LSM14B | LSM2 | LSM3 | LSM4 | LSM5 | LSM6 | LSM7 | LSM8 | LSMEM1 | LSMEM2 | LSP1 | LSP1P2 | LSP1P3 | LSP1P4 | LSP1P5 | LSR | LSS | LST1 | LTA | LTA4H | LTB | LTB4R | LTB4R2 | LTBP1 | LTBP2 | LTBP3 | LTBP4 | LTBR | LTC4S | LTF | LTK | LTN1 | LTO1 | LTV1 | LUADT1 | LUC7L | LUC7L2 | LUC7L3 | LUCAT1 | LUM | LUNAR1 | LURAP1 | LURAP1L | LURAP1L-AS1 | Luteinizing hormone | LUZP1 | LUZP2 | LUZP4 | LUZP6 | LVRN | LXN | LY6D | LY6E | LY6E-DT | LY6G5B | LY6G5C | LY6G6C | LY6G6D | LY6G6E | LY6G6F | LY6H | LY6K | LY75 | LY75-CD302 | LY86 | LY86-AS1 | LY9 | LY96 | LYAR | LYG1 | LYG2 | LYL1 | Lymphocyte antigen 6 complex | LYN | LYNX1